Investigations of the endocannabinoid system in adipose tissue

Danish Medical Bulletin

Volumn 58, Issue 4, 2011, Pages

  Bennetzen, Marianne Faurholt ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABIS; DRONABINOL; ENDOCANNABINOID; GHRELIN; GLUCOSE; GLYCEROL; INSULIN; LEPTIN; NEUROPEPTIDE Y; PLACEBO; RIMONABANT; SYNTAGON; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ABDOMINAL SUBCUTANEOUS FAT; ADIPOCYTE; ADIPOSE TISSUE; ALZHEIMER DISEASE; ANXIETY DISORDER; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; DEPRESSION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; ENERGY EXPENDITURE; FOOD INTAKE; GENE EXPRESSION; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID OXIDATION; LIVER; NAUSEA; NONHUMAN; OBESITY; PANCREAS; PROTEIN EXPRESSION; SEX DIFFERENCE; SLEEP DISORDER; SUICIDE; SYNAPTIC TRANSMISSION; TACHYPHYLAXIA; TISSUE METABOLISM; WASTING SYNDROME; WEIGHT REDUCTION;

EID: 79955413768     PISSN: 16039629     EISSN: 16039629     Source Type: Journal    
DOI: None     Document Type: Article

References (255)

1. Das UN. Obesity: Genes, brain, gut, and environment. Nutrition 2010;26(5):459-73.
2. Richelsen B, Astrup A, Hansen GL, Hansen HS, Heitmann BL, Holm L., et al. Den danske fedmeepidemi, oplag til en forebyggelsesindsats, en rapport fra Ernaringsradet. Kobenhavn: Ernaringsradet; 2003.
3. BMI classification. www who int 2010 June 8 [cited 2010 Jun 8]; Available from: URL: http://apps.who.int/bmi/index.jsp?introPage=intro_3.html
4. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004 Aug;53(8):2087-94.
5. van H, V, Dicker A, Ryden M, Hauner H, Lonnqvist F, Naslund E, et al. Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes 2002 Jul;51(7):2029-36.
6. Bruun JM, Richelsen B. [Measurement of body mass index and waist and hip circumference in adults]. Ugeskr Laeger 2009 Oct 19;171(43):3071-2.
7. Richelsen B, Bruun JM, Pedersen SB. [Fatty tissue as a secretory organ. Significance for obesity-related diseases]. Ugeskr Laeger 2001 May 21;163(21):2913-7.
8. Jorgensen LN, Ravlo O, Richelsen B. [The obese patient]. Ugeskr Laeger 2006 Dec 4;168(49):4303-5.
9. Aronne LJ, Pagotto U, Foster GD, Davis SN. The endocannabinoid system as a target for obesity treatment. Clin Cornerstone 2008;9(1):52-64.
10. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002 Dec 1;156(11):1070-7.
11. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994 Sep;17(9):961-9.
12. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002 Dec 4;288(21):2709-16.
13. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27, 000 participants from 52 countries: a casecontrol study. Lancet 2005 Nov 5;366(9497):1640-9.
14. Despres JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001 Mar 24;322(7288):716-20.
15. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet 2005 Sep 24;366(9491):1059-62.
16. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005 Jan 5;293(1):43-53.
17. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002 Feb 19;105(7):804-9.
18. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002;346(6):393-403.
19. Pi-Sunyer FX. The relation of adipose tissue to cardiometabolic risk. Clin Cornerstone 2007;8(SUPPL. 4).
20. Christiansen T, Paulsen SK, Bruun JM, Overgaard K, Ringgaard S, Pedersen SB, et al. Comparable reduction of the visceral adipose tissue depot after a diet-induced weight loss with or without aerobic exercise in obese subjects: a 12-week randomized intervention study. Eur J Endocrinol 2009 May;160(5):759-67.
21. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004;(3):CD004094.
22. Hutton B, Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 2004 Dec;80(6):1461-8.
23. Wadden TA. Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials. Ann Intern Med 1993 Oct 1;119(7 Pt 2):688-93.
24. Christiansen T, Bruun JM, Madsen EL, Richelsen B. Weight loss maintenance in severely obese adults after an intensive lifestyle intervention: 2-to 4-year follow-up. Obesity (Silver Spring) 2007 Feb;15(2):413-20.
25. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004 Dec 23;351(26):2683-93.
26. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007 Aug 23;357(8):741-52.
27. Atkinson TJ. Central and peripheral neuroendocrine peptides and signalling in appetite regulation: considerations for obesity pharmacotherapy. Obesity Reviews 2008;9(2):108-20.
28. Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, et al. Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 2003 Mar;27(3):289-301.
29. Carracedo A, Gironella M, Lorente M, Garcia S, Guzman M, Velasco G, et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 2006 Jul 1;66(13):6748-55.
30. Blazquez C, Carracedo A, Barrado L, Real PJ, Fernandez-Luna JL, Velasco G, et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 2006 Dec;20(14):2633-5.
31. Wagner JA, Abesser M, Harvey-White J, Ertl G. 2-Arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts. J Cardiovasc Pharmacol 2006 May;47(5):650-5.
32. Lim SY, Davidson SM, Yellon DM, Smith CC. The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction. Basic Res Cardiol 2009;104(6):781-92.
33. Matias I, Bisogno T, Di M, V. Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. Int J Obes (Lond) 2006 Apr;30 Suppl 1:S7-S12.
34. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994 Aug 22;350(2-3):240-4.
35. Meltzer HY, Arvanitis L, Bauer D, Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004 Jun;161(6):975-84.
36. Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev 2007;(4):CD005353.
37. Wilkinson PB. cannabis indica: an historical and pharmacological study of the drug. The British Journal of Inebriety 1929 Oct;27:72-80.
38. Chopra RN, chopra G.S. Present position of hemp drug addiction in India. The British Journal of Inebriety 1940;38(2):71-4.
39. Tart CT. Marijuana intoxication common experiences. Nature 1970 May 23;226(5247):701-4.
40. Holliste LE. Hunger and Appetite After Single Doses of Marihuana, Alcohol, and Dextroamphetamine. Clinical Pharmacology & Therapeutics 1971;12(1):44-&.
41. Abel EL. Effects of marihuana on the solution of anagrams, memory and appetite. Nature 1971 May 28;231(5300):260-1.
42. Abel EL. Cannabis: effects on hunger and thirst. Behav Biol 1975 Nov;15(3):255-81.
43. Greenberg I, Kuehnle J, Mendelson JH, Bernstein JG. Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology (Berl) 1976 Aug 26;49(1):79-84.
44. Gaoni Y, Mechoulam R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hasish. Journal of the American Chemical Society 1964 Apr 20;86:1646-7.
45. Gorter RW. Cancer cachexia and cannabinoids. Forsch Komplementarmed 1999 Oct;6 Suppl 3:21-2.
46. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995 Feb;10(2):89-97.
47. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1997 Sep;12(9):913-9.
48. Di M, V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001 Apr 12;410(6830):822-5.
49. Andre A, Gonthier MP. The endocannabinoid system: Its roles in energy balance and potential as a target for obesity treatment. Int J Biochem Cell Biol. In press 2010.
50. Devane WA, Dysarz FA, III, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988 Nov;34(5):605-13.
51. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990 Aug 9;346(6284):561-4.
52. Gerard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991 Oct 1;279 (Pt 1):129-34.
53. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365(6441):61-5.
54. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, Le FG, et al. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 1995 Feb 24;270(8):3726-31.
55. Rinaldi-Carmona M, Calandra B, Shire D, Bouaboula M, Oustric D, Barth F, et al. Characterization of two cloned human CB1 cannabinoid receptor isoforms. J Pharmacol Exp Ther 1996 Aug;278(2):871-8.
56. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 2008 Feb 19;105(7):2699-704.
57. Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002 Aug;68-69:619-31.
58. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). British Journal of Pharmacology 2000;129(2):227-30.
59. O'Sullivan SE, Tarling EJ, Bennett AJ, Kendall DA, Randall MD. Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferatoractivated receptor gamma. Biochem Biophys Res Commun 2005 Nov 25;337(3):824-31.
60. Karaliota S, Siafaka-Kapadai A, Gontinou C, Psarra K, Mavri-Vavayanni M. Anandamide increases the differentiation of rat adipocytes and causes PPARgamma and CB1 receptor upregulation. Obesity (Silver Spring) 2009;17(10):1830-8.
61. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002 Jun;54(2):161-202.
62. Matias I, Di Marzo V. Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance. J Endocrinol Invest 2006;29(3 Suppl):15-26.
63. Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, Baron JF, et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 2006 Aug;126(2):177-87.
64. Bennetzen MF, Nielsen TS, Paulsen SK, Bendix J, Fisker S, Jessen N, et al. Reduced cannabinoid receptor 1 protein in subcutaneous adipose tissue of obese. European Journal of Clinical Investigation 2010;40(2):121-6.
65. Spoto B, Fezza F, Parlongo G, Battista N, Sgro' E, Gasperi V, et al. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie 2006 Dec;88(12):1889-97.
66. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005 May;115(5):1298-305.
67. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006 Feb;27(1):73-100.
68. Di M, V, Bisogno T, De PL, Melck D, Orlando P, Wagner JA, et al. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 1999 Aug;264(1):258-67.
69. Juan-Pico P, Fuentes E, Bermudez-Silva FJ, Javier Diaz-Molina F, Ripoll C, Rodriguez de FF, et al. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 2006 Feb;39(2):155-62.
70. Coutts AA, Izzo AA. The gastrointestinal pharmacology of cannabinoids: an update. Curr Opin Pharmacol 2004 Dec;4(6):572-9.
71. Idris AI, van 't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 2005 Jul;11(7):774-9.
72. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003 Nov;4(11):873-84.
73. de Kloet AD, Woods SC. Minireview: Endocannabinoids and their receptors as targets for obesity therapy. Endocrinology 2009 Jun;150(6):2531-6.
74. Pertwee RG, Howlett AC, Abood ME, Alexander S.P.H, Di Marzo V, Elphick MR, et al. International Union of Pharmacology. Cannabinoid Receptors and their Ligands: Beyond CB1 and CB2. Pharmacology Reviews. In press 2010.
75. Turu G, Hunyady L. Signal transduction of the CB1 cannabinoid receptor. J Mol Endocrinol 2010;44(2):75-85.
76. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 2005 Jul 1;280(26):25196-201.
77. van Thuijl H, Kola B, Korbonits M. Appetite and metabolic effects of ghrelin and cannabinoids: Involvement of AMPactivated protein kinase. Vitamins and Hormones, Ghrelin 2008;77:121-48.
78. Rosenson RS. Role of the Endocannabinoid System in Abdominal Obesity and the Implications for Cardiovascular Risk. Cardiology 2009;114(3):212-25.
79. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003 Aug;112(3):423-31.
80. Ravinet TC, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004 Apr;28(4):640-8.
81. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008 Sep;118(9):3160-9.
82. Quarta C, Bellocchio L, Mancini G, Mazza R, Cervino C, Braulke LJ, et al. CB1 Signaling in Forebrain and Sympathetic Neurons Is a Key Determinant of Endocannabinoid Actions on Energy Balance. Cell Metabolism 2010;11(4):273-85.
83. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992 Dec 18;258(5090):1946-9.
84. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995 Jun 29;50(1):83-90.
85. Vandevoorde S, Lambert DM. The multiple pathways of endocannabinoid metabolism: A zoom out. Chem Biodiversity 2007;4(8):1858-81.
86. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001 Mar 27;98(7):3662-5.
87. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002 Jun;301(3):1020-4.
88. Dodd GT, Mancini G, Lutz B, Luckman SM. The Peptide Hemopressin Acts through CB1 Cannabinoid Receptors to Reduce Food Intake in Rats and Mice. Journal of Neuroscience 2010;30(21):7369-76.
89. De Petrocellis L, Di Marzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab 2009 Feb;23(1):1-15.
90. Gonthier MP, Hoareau L, Festy F, Matias I, Valenti M, Bes-Houtmann S, et al. Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring) 2007 Apr;15(4):837-45.
91. Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008 May;108(5):1687-707.
92. Sugiura T, Kishimoto S, Oka S, Gokoh M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Progress in Lipid Research 2006;45(5):405-46.
93. Gomez-Ruiz M, Hernandez M, de MR, Ramos JA. An overview on the biochemistry of the cannabinoid system. Mol Neurobiol 2007 Aug;36(1):3-14.
94. Hansen HS, Diep TA. N-acylethanolamines, anandamide and food intake. Biochem Pharmacol 2009;78(6):553-60.
95. Liu J, Wang L, Harvey-White J, Osei-Hyiaman D, Razdan R, Gong Q, et al. A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A 2006 Sep 5;103(36):13345-50.
96. Kirkham TC, Tucci SA. Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets 2006 Jun;5(3):272-92.
97. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 2001 Jul 31;98(16):9371-6.
98. Tourino C, Oveisi F, Lockney J, Piomelli D, Maldonado R. FAAH deficiency promotes energy storage and enhances the motivation for food. Int J Obes 2009.
99. Hao S, Avraham Y, Mechoulam R, Berry EM. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 2000 Mar 31;392(3):147-56.
100. Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1999 Apr;143(3):315-7.
101. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del A, I, et al. A peripheral mechanism for CB1 cannabinoid receptordependent modulation of feeding. J Neurosci 2002 Nov 1;22(21):9612-7.
102. Kirkham TC, Williams CM, Fezza F, Di M, V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002 Jun;136(4):550-7.
103. Wiley JL, Burston JJ, Leggett DC, Alekseeva OO, Razdan RK, Mahadevan A, et al. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 2005 Jun;145(3):293-300.
104. Wise LE, Shelton CC, Cravatt BF, Martin BR, Lichtman AH. Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors. Eur J Pharmacol 2007 Feb 14;557(1):44-8.
105. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005 May;8(5):585-9.
106. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le FG, Oury-Donat F, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003 Apr;63(4):908-14.
107. Schwartz MW, Woods SC, Porte D, Jr., Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000 Apr 6;404(6778):661-71.
108. Boguszewski CL, Paz G, Velloso LA. Neuroendocrine body weight regulation: integration between fat tissue, gastrointestinal tract, and the brain. Endokrynologia Polska 2010;61(2):194-206.
109. South T, Huang XF. Temporal and site-specific brain alterations in CB1 receptor binding in high fat diet-induced obesity in C57Bl/6 mice. J Neuroendocrinol 2008 Nov;20(11):1288-94.
110. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001 Apr 12;410(6830):822-5.
111. Buettner C, Muse ED, Cheng A, Chen L, Scherer T, Pocai A, et al. Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med 2008 Jun;14(6):667-75.
112. Tucci SA, Rogers EK, Korbonits M, Kirkham TC. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 2004 Nov;143(5):520-3.
113. Verty AN, Boon WM, Mallet PE, McGregor IS, Oldfield BJ. Involvement of hypothalamic peptides in the anorectic action of the CB receptor antagonist rimonabant (SR 141716). Eur J Neurosci 2009 Jun;29(11):2207-16.
114. Hermann H, Marsicano G, Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002;109(3):451-60.
115. Hilairet S, Bouaboula M, Carriere D, Le Fur G, Casellas P. Hypersensitization of the orexin 1 receptor by the CB1 receptor: Evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J Biol Chem 2003;278(26):23731-7.
116. Nogueiras R, Lopez M, Dieguez C. Regulation of lipid metabolism by energy availability: a role for the central nervous system. Obesity Reviews 2010;11(3):185-201.
117. Eckardt K, Sell H, Taube A, Koenen M, Platzbecker B, Cramer A, et al. Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia 2009 Apr;52(4):664-74.
118. Lee DE, Kehlenbrink S, Lee H, Hawkins M, Yudkin JS. Getting the message across: mechanisms of physiological cross talk by adipose tissue. Am J Physiol Endocrinol Metab 2009 Jun;296(6):E1210-E1229.
119. Osei-Hyiaman D, Harvey-White J, Batkai S, Kunos G. The role of the endocannabinoid system in the control of energy homeostasis. Int J Obes (Lond) 2006 Apr;30 Suppl 1:S33-S38.
120. Horvath TL. The unfolding cannabinoid story on energy homeostasis: central or peripheral site of action? Int J Obes (Lond) 2006 Apr;30 Suppl 1:S30-S32.
121. Kunos G, Osei-Hyiaman D, Liu J, Godlewski G, Batkai S. Endocannabinoids and the control of energy homeostasis. J Biol Chem 2008 Nov 28;283(48):33021-5.
122. Kunos G, Osei-Hyiaman D, Batkai S, Sharkey KA, Makriyannis A. Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci 2009 Jan;30(1):1-7.
123. Esposito I, Proto MC, Gazzerro P, Laezza C, Miele C, Alberobello AT, et al. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol 2008 Dec;74(6):1678-86.
124. Cavuoto P, Wittert GA. The role of the endocannabinoid system in the regulation of energy expenditure. Best Pract Res Clin Endocrinol Metab 2009 Feb;23(1):79-86.
125. Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschop J, Caldwell C, et al. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 2008 Nov;57(11):2977-91.
126. Martin-Garcia E, Burokas A, Martin M, Berrendero F, Rubi B, Kiesselbach C, et al. Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant. J Neurochem 2010 Mar;112(5):1338-13351.
127. Verty ANA, Allen AM, Oldfield BJ. The effects of rimonabant on brown adipose tissue in rat: Implications for energy expenditure. Obesity 2009;17(2):254-61.
128. Madsen AN, Jelsing J, van de Wall EH, Vrang N, Larsen PJ, Schwartz GJ. Rimonabant induced anorexia in rodents is not mediated by vagal or sympathetic gut afferents. Neurosci Lett 2009 Jan 2;449(1):20-3.
129. Son MH, Kim HD, Chae YN, Kim MK, Shin CY, Ahn GJ, et al. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control. Int J Obes 2009.
130. Nieri P, Greco R, Adinolfi B, Breschi MC, Martinotti E, Nannetti C, et al. CB1-and CB2-cannabinoid receptorindependent lipolysis induced by WIN 55, 212-2 in male rat adipocytes. Naunyn Schmiedebergs Arch Pharmacol 2003;368(5):352-9.
131. Gasperi V, Fezza F, Pasquariello N, Bari M, Oddi S, Agro AF, et al. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci 2007 Jan;64(2):219-29.
132. Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006;69(2):471-8.
133. Matias I, Gonthier MP, Orlando P, Martiadis V, De PL, Cervino C, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006 Aug;91(8):3171-80.
134. Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE, et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005 Jan;7(1):65-72.
135. Bennetzen MF, Nielsen MP, Richelsen B, Pedersen SB. Effects on food intake and blood lipids of cannabinoid receptor 1 antagonist treatment in lean rats. Obesity (Silver Spring) 2008 Nov;16(11):2451-5.
136. Cota D, Sandoval DA, Olivieri M, Prodi E, D'Alessio DA, Woods SC, et al. Food Intake-independent Effects of CB1 Antagonism on Glucose and Lipid Metabolism. Obesity (Silver Spring) 2009 Aug;17(8):1641-5.
137. Florentin M, Liberopoulos EN, Tellis CC, Derdemezis CS, Elisaf M, Tselepis A. Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: A pilot study. Angiology 2010;61(4):365-71.
138. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 2005 Feb;6(1):13-21.
139. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999 Apr 2;257(1):79-83.
140. Lihn AS, Jessen N, Pedersen SB, Lund S, Richelsen B. AICAR stimulates adiponectin and inhibits cytokines in adipose tissue. Biochem Biophys Res Commun 2004 Apr 9;316(3):853-8.
141. Watanabe T, Kubota N, Ohsugi M, Kubota T, Takamoto I, Iwabu M, et al. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectinindependent pathways. J Biol Chem 2008 Nov 13.
142. Migrenne S, Lacombe A, Lefevre AL, Pruniaux MP, Guillot E, Galzin AM, et al. Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2009 Apr;296(4):R929-R935.
143. Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G, et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007 Dec;92(12):4810-9.
144. Motaghedi R, McGraw TE. The CB1 endocannabinoid system modulates adipocyte insulin sensitivity. Obesity (Silver Spring) 2008 Aug;16(8):1727-34.
145. Mohapatra J, Sharma M, Singh S, Pandya G, Chatterjee A, Balaraman R, et al. Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice. J Pharm Pharmacol 2009 Nov;61(11):1493-8.
146. Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, Izzo AA, et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 2008 Mar;16(3):553-65.
147. Jourdan T, Djaouti L, Demizieux L, Gresti J, Verges B, Degrace P. CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese Mice. Diabetes 2010;59(4):926-34.
148. Molhoj S, Hansen HS, Schweiger M, Zimmermann R, Johansen T, Malmlof K. Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats. Eur J Pharmacol.
149. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 2005 Feb;29(2):183-7.
150. Kunz I, Meier MK, Bourson A, Fisseha M, Schilling W. Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats. Int J Obes (Lond) 2008 May;32(5):863-70.
151. Lindborg KA, Henriksen EJ. Direct effects of endocannabinoid receptor antagonism on the glucose transport system in insulin-resistant skeletal muscle of the obese Zucker rat. FASEB J 2009;23(S1).
152. Lindborg KA, Teachey MK, Jacob S, Henriksen EJ. Effects of in vitro antagonism of endocannabinoid-1 receptors on the glucose transport system in normal and insulin-resistant rat skeletal muscle. Diabetes Obesity & Metabolism 2010;12(8):722-30.
153. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Triflou C, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007;46(1):122-9.
154. Nakata M, Yada T. Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet beta-cells via CB1 receptors. Regul Pept 2008 Jan 10;145(1-3):49-53.
155. Bermudez-Silva FJ, Suarez J, Baixeras E, Cobo N, Bautista D, Cuesta-Munoz AL, et al. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 2008 Mar;51(3):476-87.
156. Tharp WG, Lee YH, Maple RL, Pratley RE. The cannabinoid CB1 receptor is expressed in pancreatic delta-cells. Biochemical and Biophysical Research Communications 2008;372(4):595-600.
157. Getty-Kaushik L, Richard AM, Deeney JT, Krawczyk S, Shirihai O, Corkey BE. The CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic islets. Obesity (Silver Spring) 2009 Oct;17(10):1856-60.
158. D'Eon TM, Pierce KA, Roix JJ, Tyler A, Chen H, Teixeira SR. The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes 2008 May;57(5):1262-8.
159. Bermudez-Silva FJ, Suarez PJ, Nadal A, Rodriguez de FF. The role of the pancreatic endocannabinoid system in glucose metabolism. Best Pract Res Clin Endocrinol Metab 2009 Feb;23(1):87-102.
160. Yan ZC, Liu DY, Zhang LL, Shen CY, Ma QL, Cao TB, et al. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferatoractivated receptor-delta. Biochem Biophys Res Commun 2007 Mar 9;354(2):427-33.
161. Muccioli GG, Naslain D, Backhed F, Reigstad CS, Lambert DM, Delzenne NM, et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol 2010 Jul 27;6:392.
162. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998;63(8):L113-L117.
163. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999;283(5400):401-4.
164. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 1999;96(10):5780-5.
165. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascioll MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002;418(6897):530-4.
166. Valverde O, Karsak M, Zimmer A. Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. Handb Exp Pharmacol 2005;(168):117-45.
167. Ravinet TC, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003 Feb;284(2):R345-R353.
168. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 2003 Apr;167(1):103-11.
169. Rigamonti AE, Giordani C, Bonomo SM, Cella SG, Muller EE. Early tolerance to the hypophagic effect of the cannabinoid receptor antagonist SR141716 does not impede blockade of an orexigenic stimulus. Eur J Pharmacol 2006 Aug 7;542(1-3):116-20.
170. Chambers AP, Sharkey KA, Koopmans HS. Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat. Physiology and Behavior 2004;82(5):863-9.
171. Thornton-Jones ZD, Kennett GA, Benwell KR, Revell DF, Misra A, Sellwood DM, et al. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav 2006 Jun;84(2):353-9.
172. Irwin N, Hunter K, Frizzell N, Flatt PR. Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB(1)) antagonist, AM251, in obese diabetic (ob/ob) mice. Eur J Pharmacol 2008;581(1-2):226-33.
173. Herling AW, Kilp S, Elvert R, Haschke G, Kramer W. Increased energy expenditure contributes more to the body weightreducing effect of rimonabant than reduced food intake in candy-fed Wistar rats. Endocrinology 2008;149(5):2557-66.
174. Perwitz N, Wenzel J, Wagner I, Buning J, Drenckhan M, Zarse K, et al. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. Diabetes Obesity & Metabolism 2010;12(2):158-66.
175. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005 Sep;19(11):1567-9.
176. Tedesco L, Valerio A, Cervino C, Cardile A, Pagano C, Vettor R, et al. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes 2008;57(8):2028-36.
177. Simiand J, Keane M, Keane PE, Soubrie P. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 1998 Mar;9(2):179-81.
178. Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 1997;132(1):104-6.
179. Droste SM, Saland SK, Schlitter EK, Rodefer JS. AM 251 differentially effects food-maintained responding depending on food palatability. Pharmacol Biochem Behav 2010;95(4):443-8.
180. Gessa GL, Orru A, Lai P, Maccioni P, Lecca R, Lobina C, et al. Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats. Psychopharmacology (Berl) 2006 Apr;185(2):248-54.
181. Maccioni P, Pes D, Carai MAM, Gessa GL, Colombo G. Suppression by the cannabinoid CB1 receptor antagonist, rimonabant, of the reinforcing and motivational properties of a chocolate-flavoured beverage in rats. Behav Pharmacol 2008;19(3):197-209.
182. Ward SJ, Dykstra LA. The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav Pharmacol 2005;16(5-6):381-8.
183. Mathes CM, Ferrara M, Rowland NE. Cannabinoid-1 receptor antagonists reduce caloric intake by decreasing palatable diet selection in a novel dessert protocol in female rats. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 2008;295(1):R67-R75.
184. Koolman AH, Bloks VW, Oosterveer MH, Jonas I, Kuipers F, Sauer PJJ, et al. Metabolic responses to long-term pharmacological inhibition of CB1-receptor activity in mice in relation to dietary fat composition. Int J Obes 2009.
185. Escartin-Perez RE, Cendejas-Trejo NM, Cruz-Martinez AM, Gonzalez-Hernandez B, Mancilla-Diaz JM, Floran-Garduno B. Role of cannabinoid CB1 receptors on macronutrient selection and satiety in rats. Physiol Behav 2009 Mar 23;96(4-5):646-50.
186. DiPatrizio NV, Simansky KJ. Activating parabrachial cannabinoid CB1 receptors selectively stimulates feeding of palatable foods in rats. J Neurosci 2008 Sep 24;28(39):9702-9.
187. Harrold JA, Elliott JC, King PJ, Widdowson PS, Williams G. Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Research 2002;952(2):232-8.
188. Melis T, Succu S, Sanna F, Boi A, Argiolas A, Melis MR. The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food. Neurosci Lett 2007 Jun 4;419(3):231-5.
189. Rasmussen EB, Huskinson SL. Effects of rimonabant on behavior maintained by progressive ratio schedules of sucrose reinforcement in obese Zucker (fa/fa) rats. Behav Pharmacol 2008 Oct;19(7):735-42.
190. Berridge KC, Ho CY, Richard JM, DiFeliceantonio AG. The tempted brain eats: Pleasure and desire circuits in obesity and eating disorders. Brain Res 2010 Apr 11.
191. Kirkham TC. Cannabinoids and appetite: food craving and food pleasure. Int Rev Psychiatry 2009 Apr;21(2):163-71.
192. Izzo AA, Piscitelli F, Capasso R, Aviello G, Romano B, Borrelli F, et al. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. British Journal of Pharmacology 2009;158(2):451-61.
193. Batetta B, Griinari M, Carta G, Murru E, Ligresti A, Cordeddu L, et al. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr 2009 Aug;139(8):1495-501.
194. Zhou D, Shearman LP. Voluntary exercise augments acute effects of CB1-receptor inverse agonist on body weight loss in obese and lean mice. Pharmacol Biochem Behav 2004 Jan;77(1):117-25.
195. O'Rourke RW. Inflammation in obesity-related diseases. Surgery 2009 Mar;145(3):255-9.
196. Kempf K, Hector J, Strate T, Schwarzloh B, Rose B, Herder C, et al. Immune-mediated activation of the endocannabinoid system in visceral adipose tissue in obesity. Horm Metab Res 2007 Aug;39(8):596-600.
197. Rajesh M, Mukhopadhyay P, Hasko G, Liaudet L, Mackie K, Pacher P. Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and-independent mitogenactivated protein kinase activation and cell death in human coronary artery endothelial cells. British Journal of Pharmacology 2010;160(3):688-700.
198. Sugamura K, Sugiyama S, Nozaki T, Matsuzawa Y, Izumiya Y, Miyata K, et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009 Jan 6;119(1):28-36.
199. Kolb H, Mandrup-Poulsen T. The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation. Diabetologia 2010 Jan;53(1):10-20.
200. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005 Nov 17;353(20):2121-34.
201. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nature Reviews Immunology 2005;5(5):400-11.
202. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005 Oct;54(10):2838-43.
203. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres JP, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007 Apr;31(4):692-9.
204. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006 Nov;55(11):3053-60.
205. Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF, et al. Biomarkers of Endocannabinoid System Activation in Severe Obesity. PLoS ONE 2010;5(1).
206. Annuzzi G, Piscitelli F, Di Marino L, Patti L, Giacco R, Costabile G, et al. Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids in Health and Disease 2010;43.
207. Sarzani R, Bordicchia M, Marcucci P, Bedetta S, Santini S, Giovagnoli A, et al. Altered pattern of cannabinoid type 1 receptor expression in adipose tissue of dysmetabolic and overweight patients. Metabolism 2009 Mar;58(3):361-7.
208. Lofgren P, Sjolin E, Wahlen K, Hoffstedt J. Human adipose tissue cannabinoid receptor 1 gene expression is not related to fat cell function or adiponectin level. J Clin Endocrinol Metab 2007 Apr;92(4):1555-9.
209. Murdolo G, Kempf K, Hammarstedt A, Herder C, Smith U, Jansson PA. Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals. Journal of Endocrinological Investigation 2007;30:RC17-RC21.
210. Lee YH, Tharp WG, Dixon AE, Spaulding L, Trost S, Nair S, et al. Dysregulation of Cannabinoid CB1 Receptor Expression in Subcutaneous Adipocytes of Obese Individuals. Animal Cells and Systems 2009;13(4):371-9.
211. Peeters A, Beckers S, Mertens I, Van Hul W, Van Gaal L. The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men. Endocrine 2007;31(2):138-41.
212. Muller TD, Reichwald K, Wermter AK, Bronner G, Nguyen TT, Friedel S, et al. No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents. Molecular Genetics and Metabolism 2007;90(4):429-34.
213. Schleinitz D, Carmienke S, Bottcher Y, Tnjes A, Berndt J, Kloting N, et al. Role of genetic variation in the cannabinoid type 1 receptor gene (CNR1) in the pathophysiology of human obesity. Pharmacogenomics 2010;11(5):693-702.
214. Tiwari AK, Zai CC, Likhodi O, Lisker A, Singh D, Souza RP, et al. A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is Associated with Antipsychotic-Induced Weight Gain in Schizophrenia. Neuropsychopharmacology 2010;35(6):1315-24.
215. Benzinou M, Chvre JC, Ward KJ, Lecoeur C, Dina C, Lobbens S, et al. Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. Human Molecular Genetics 2008;17(13):1916-21.
216. Jaeger JP, Mattevi VS, Callegari-Jacques SM, Hutz MH. Cannabinoid type-1 receptor gene polymorphisms are associated with central obesity in a Southern Brazilian population. Dis Markers 2008;25(1):67-74.
217. Baye TM, Zhang Y, Smith E, Hillard CJ, Gunnell J, Myklebust J, et al. Genetic variation in cannabinoid receptor 1 (CNR1) is associated with derangements in lipid homeostasis, independent of body mass index. Pharmacogenomics 2008 Nov;9(11):1647-56.
218. Wilke RA, Chiu S, Ruby M, Krauss RM. Genetic variability in CNR1 is associated with diet-induced changes in fasting triglyceride levels. Clin Pharmacol Ther 2010;87:S19.
219. Pillarisetti S, Alexander CW, Khanna I. Pain and beyond: fatty acid amides and fatty acid amide hydrolase inhibitors in cardiovascular and metabolic diseases. Drug Discov Today 2009 Dec;14(23-24):1098-111.
220. Di M, V, Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci 2008 May;29(5):229-33.
221. Jensen DP, Andreasen CH, Andersen MK, Hansen L, Eiberg H, Borch-Johnsen K, et al. The functional Pro129Thr variant of the FAAH gene is not associated with various fat accumulation phenotypes in a population-based cohort of 5, 801 whites. Journal of Molecular Medicine-Jmm 2007;85(5):445-9.
222. Papazoglou D, Panagopoulos I, Papanas N, Gioka T, Papadopoulos T, Papathanasiou P, et al. The Fatty Acid Amide Hydrolase (FAAH) Pro129Thr Polymorphism is not Associated with Severe Obesity in Greek Subjects. Hormone and Metabolic Research 2008;40(12):907-10.
223. Durand E, Lecoeur C, Delplanque J, Benzinou M, Degraeve F, Boutin P, et al. Evaluating the association of FAAH common gene variation with childhood, adult severe obesity and type 2 diabetes in the French population. Obes Facts 2008;1(6):305-9.
224. Aberle J, Fedderwitz I, Klages N, George E, Beil FU. Genetic variation in two proteins of the endocannabinoid system and their influence on body mass index and metabolism under low fat diet. Horm Metab Res 2007 May;39(5):395-7.
225. Zhang Y, Sonnenberg GE, Baye TM, Littrell J, Gunnell J, DeLa-Forest A, et al. Obesity-related dyslipidemia associated with FAAH, independent of insulin response, in multigenerational families of Northern European descent. Pharmacogenomics 2009;10(12):1929-39.
226. Muller TD, Bronner G, Wandolski M, Carrie J, Nguyen TT, Greene BH, et al. Mutation screen and association studies for the fatty acid amide hydrolase (FAAH) gene and early onset and adult obesity. Bmc Medical Genetics 2010;11.
227. Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes (Lond) 2005 Jul;29(7):755-9.
228. Monteleone P, Tortorella A, Martiadis V, Di Filippo C, Canestrelli B, Maj M. The cDNA 385C to A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) is associated with overweight/obesity but not with binge eating disorder in overweight/obese women. Psychoneuroendocrinology 2008;33(4):546-50.
229. de Luis DA, Gonzalez Sagrado M, Aller R, Izaola O, Conde R, Romero E. C358A missense polymorphism of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) and visfatin levels in obese females. Int J Obes 2010.
230. Lieb W, Manning AK, Florez JC, Dupuis J, Cupples LA, McAteer JB, et al. Variants in the CNR1 and the FAAH Genes and Adiposity Traits in the Community. Obesity 2009;17(4):755-60.
231. Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005 Feb 4;76(12):1307-24.
232. Pi-Sunyer FX, Despres JP, Scheen A, Van Gaal L. Improvement of metabolic parameters with rimonabant beyond the effect attributable to weight loss alone: Pooled 1-year data from the RIO (rimonabant in obesity and related metabolic disorders) program. Journal of the American College of Cardiology 2006;47(4):362A.
233. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007 Nov 17;370(9600):1706-13.
234. Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 2009 Jul;205(1):171-4.
235. Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane Database of Systematic Reviews 2006;(4).
236. Fong TM, Addy C, Erondu N, Heymsfield SB. CB1 receptor inverse agonist pharmacotherapy for metabolic disorders. Drug Dev Res 2009;70(8):566-76.
237. Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008 Apr 2;299(13):1547-60.
238. Rosenstock J, Hollander P, Chevalier S, Iranmanesh A. SERENADE: the Study Evaluating Rimonabant Efficacy in Drugnaive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 2008 Nov;31(11):2169-76.
239. Despres JP, Ross R, Boka G, Almeras N, Lemieux I. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009 Mar;29(3):416-23.
240. Hollander PA, Amod A, Litwak LE, Chaudhari U. Effect of Rimonabant on Glycemic Control in Insulin-Treated Type 2 Diabetes: The ARPEGGIO Trial. Diabetes Care 2010;33(3):605-7.
241. Heppenstall C, Chakera A, Bunce S, Smith JC. The effects of the anti-obesity drug rimonabant on blood glucose, energy intake and dietary composition in obese adults with type 2 diabetes. Diabet Med 2010;27(2):46-7.
242. Engeli S, Lehmann AC, Bohnke J, Janke J, Gorzelniak K, Strauss A, et al. Influence of BMI and dietary fat intake on the expression of endocannabinoid-system genes in human adipose tissue and skeletal muscle. Basic Clin Pharmacol Toxicol 2009;104(6):520-1.
243. Cavuoto P, McAinch AJ, Hatzinikolas G, Cameron-Smith D, Wittert GA. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Molecular and Cellular Endocrinology 2007;267:63-9.
244. Di Marzo V, Verrijken A, Hakkarainen A, Petrosino S, Mertens I, Lundbom N, et al. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 2009 Nov;161(5):715-22.
245. Scherer T, Buettner C. The dysregulation of the endocannabinoid system in diabesity-a tricky problem. J Mol Med 2009;87(7):663-8.
246. Engeli S, Heusser K, Janke J, Gorzelniak K, Batkai S, Pacher P, et al. Peripheral endocannabinoid system activity in patients treated with sibutramine. Obesity (Silver Spring) 2008 May;16(5):1135-7.
247. Di Marzo V, Cote M, Matias I, Lemieux I, Arsenault BJ, Cartier A, et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 2009 Feb;52(2):213-7.
248. Madsen EL, Rissanen A, Bruun JM, Skogstrand K, Tonstad S, Hougaard DM, et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008 Feb;158(2):179-87.
249. Tam J, Ofek O, Fride E, Ledent C, Gabet Y, Muller R, et al. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 2006 Sep;70(3):786-92.
250. Smith SL, Rasmussen EB. Effects of 2-AG on the reinforcing properties of wheel activity in obese and lean Zucker rats. Behav Pharmacol. In press 2010.
251. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 Jul;28(7):412-9.
252. Systeme International (SI) units for plasma, serum, or blood concentrations. Diabetes 1993;42(3):370-1.
253. Vaughn LK, Denning G, Stuhr KL, de Wit H, Hill MN, Hillard CJ. Endocannabinoid signalling: has it got rhythm? British Journal of Pharmacology 2010;160(3):530-43.
254. Benarroch EE. Neural control of feeding behavior: Overview and clinical correlations. Neurology 2010;74(20):1643-50.
255. Bermudez-Silva FJ, Viveros MP, McPartland JM, Rodriguez de FF. The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav 2010 Jun;95(4):375-82.